Metalloproteases in remodeling of vascular extracellular matrix

Fibrinolysis and Proteolysis

Volumn 13, Issue 2, 1999, Pages 54-63

  Galis, Z S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MATRIX METALLOPROTEINASE;

ADAPTATION; ANGIOGENESIS; ATHEROSCLEROSIS; CELL INTERACTION; CELL PROLIFERATION; ENZYME ACTIVITY; ENZYME DEGRADATION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; INFLAMMATORY CELL; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM; WOUND HEALING;

EID: 0033064880     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(99)90080-2     Document Type: Review

References (135)

1. Woessner JF Jr. The family of matrix metalloproteinases. Ann N Y Acad Sci 1994; 732: 11-21.
2. Van Wart HE, Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci USA 1990; 87: 5578-5582.
3. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997; 74: 111-122.
4. Murphy G. Matrix metalloproteinases and their inhibitors. Acta Orthop Scand 1995; 266 (suppl) 55-60.
5. Wilhelm SM, Eisen AZ, Teter M, Clark SD, Kronberger A, Goldberg G. Human fibroblast collagenase: glycosylation and tissue-specific levels of enzyme synthesis. Proc Natl Acad SCi USA 1986; 83: 3756-3760.
6. Chin JR, Murphy G, Werb Z. Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization, and substrates. J Biol Chem 1985; 260: 12367-12376.
7. Murphy G, Cockett MI, Stephens P, Smith BJ, Docherthy AJP. Stromelysin is an activator of procollagenase. Biochem J 1987; 248: 265-268.
8. Ogata Y, Enghild JJ, Nagase H. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 1992; 267: 3581-3584.
9. Murphy G, Cockett MI, Ward RV, Docherty AJ. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activiates of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J 1991; 277: 277-279.
10. Senior RM, Griffin GL, Fliszar CJ, Shapiro SD, Goldberg GI, Welgus HG. Human 92- and 72-kilodalton type IV collagenases are elastases. J Biol Chem 1991; 266: 7870-7875.
11. Katsuda S, Okada Y, Okada Y, Imai K, Nakanishi I. Matrix metalloproteinase-9 (92-kd gelatinase type IV collagenase equals gelatinase B) can degrade arterial elastin. Am J Pathol 1994; 145: 1208-1218.
12. Aimes RT, Quigley JP. Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4- and 1/4-length fragments. J Biol Chem 1995; 270: 5872-5876.
13. Sato H, Takino T, Okada Y et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 1994; 370: 61-65.
14. Sato H, Okada Y, Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thrombosis & Haemostasis 1997; 78: 497-500.
15. d'Ortho MP, Will H, Atkinson S et al. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 1997; 250: 751-757.
16. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-557.
17. Levi E, Fridman R, Miao HQ, Ma YS, Yayon A, Vlodavsky I. Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 7069-7074.
18. Ugwu F, Van Hoef B, Bini A, Collen D, Lijnen HR. Proteolytic cleavage of urokinase-type plasminogen activator by stromelysin-1 (MMP-3). Biochemistry 1998; 37: 7231-7236.
19. Lijnen HR, Ugwu F, Bini A, Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 1998; 37: 4699-4702.
20. Murphy G, Hembry RM, Hughes CE, Fosang AJ, Hardingham TE. Role and regulation of metalloproteinases in connective tissue turnover. Biochem. Soc. Trans. 1990; 18: 812-815.
21. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991; 64: 327-336.
22. Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991; 5: 2145-2154.
23. Stetler-Stevenson WG, Liotta LA, Kleiner DE. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEBJ 1993; 7: 1434-1441.
24. Gimbrone MA, Jr. Vascular endothelium: an integrator of pathophysiologic stimuli in atherosclerosis [see comments]. Am J Cardiol 1995; 75: 67B-70B.
25. Herron GS, Werb Z, Dwyer K, Banda MJ. Secretion of metalloproteinases by stimulated capillary endothelial cells. I. Production of procollagenase and prostromelysin exceeds expression of proteolytic activity. J Biol Chem 1986; 261: 2810-2813.
26. Hanemaaijer R, Koolwijk P, le Clercq L, de Vree WJ, van Hinsbergh VW. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J 1993; 296: 803-809.
27. Herron GS, Banda MJ, Clark EJ, Gavrilovic J, Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J Biol Chem 1986; 261: 2814-2818.
28. Zucker S, Conner C, DiMassmo BI et al. Thrombin induces the activation of progelatinase A in vascular endothelial cells. Physiologic regulation of angiogenesis. J Biol Chem 1995; 270: 23730-23738.
29. Haas TL, Davis SJ, Madri JA. Three-dimensional type I collagen lattices induce coordiante expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 1998; 273: 3604-3610.
30. Rajavashisth TB, Galis ZS, Liao JK, Libby P. Cytokines increase the expression of membrane type-matrix metalloproteinase in cultured human vascular cells. Circulation 1995; 92: A0810.
31. Stary HC, Blankenhorn DH, Chandler AB et al. A definition of intima of human arteries and of its atherosclerosis-prone regions: a report from the Committee on Vascular Lesions of the Council on Atherosclerosis, American Heart Association. Circulation. 1992; 85: 391-405.
32. Yanagi H, Sasaguri Y, Sugama K, Morimatsu M, Nagase H. Production of tissue collagenase (matrix metalloproteinase1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis. 1991; 91: 207-216
33. Evans CH, Georgescu HI, Lin CW, Mendelow D, Steed DL, Webster MW. Inducible synthesis of collagenase and other neutral metalloproteinaases by cells of aortic origin. J Surg Res 1991; 51: 399-404.
34. Southgate KM, Davies M, Booth RF, Newby AC. Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem. J. 1992; 288: 93-99.
35. Au YP, Kenagy RD, Clowes AW. Heparin selectively inhibits the transcription of tissue-type plasminogen activator in primate arterial smooth muscle cells during mitogenesis. J Biol Chem 1992; 267: 3438-3444.
36. Pauly RR, Passaniti A, Bilato C et al. Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994; 75: 41-54.
37. Galis ZS, Muszynski M, Sukhova GK et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 1994; 75: 181-189.
38. Goetzl EJ, Banda MJ, Leppert D. Matrix metalloproteinases in immunity. J Immunol 1996; 156: 1-4.
39. Klurfeld DM. Identification of foam cells in human atherosclerotic lesions as macrophages using monoclonal antibodies. Arch Pathol Lab Med 1985; 109: 445-449.
40. Aqel NM, Ball RY, Waldmann H, Mitchinson MJ. Identification of macrophages and smooth muscle cells in human atherosclerosis using monoclonal antibodies. J Pathol 1985; 146: 197-204.
41. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis 1986; 6: 131-138.
42. Stary HC. Macrophages, macrophage foam cells, and eccentric intimal thickening in the coronary arteries of young children. Atherosclerosis 1987; 64: 91-108.
43. Ross R. Rous-Whipple Award Lecture. Atherosclerosis: a defense mechanism gone awry. Am J Pathol 1993; 143: 987-1002.
44. Henney AM, Wakeley PR, Davies MJ et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Nad Acad Sci USA. 1991; 88: 8154-8154.
45. Galis ZS, Sukhova GK, Muszynski M, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metallaproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions Atherosclerosis III: recent advances in atherosclerosis research. 1995; 748: 501-507.
46. Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995; 92: 402-406.
47. Werb Z, Banda MJ, Jones PA. Degradation of connective tissue matrices by macrophages. I. Proteolysis of elastin, glycoproteins, and collagen by proteinases isolated from macrophages. J Exp Med 1980; 152: 1340-1357.
48. Senior RM, Connolly NL, Cury JD, Welgus HG, Campbell EJ. Elastin degradation by human alveolar macrophages. A prominent role of metalloproteinase activity. Am Rev Respir Dis 1989; 139: 1251-1256.
49. Welgus HG, Campbell EJ, Cury JD et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest 1990; 86: 1496-1502.
50. Campbell EJ, Cury JD, Shapiro SD, Goldberg GI, Welgus HG. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J Immunol 1991; 146: 1286-1293.
51. Wesley RI, Meng X, Godin D, Galis Z. Extracellular matrix modulates macrophage functions characteristic to atheroma: collagen I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscl Thromb Vasc Biol 1998; 432-440.
52. Xie B, Laouar A, Huberman E. Fibronectin-mediated cell adhesion is required for induction of 92-kDa type IV collagenase/gelatinase (MMP-9) gene expression during macrophage differentiation. The signaling role of protein kinase C-beta. J Biol Chem 1998; 273: 11576-11582.
53. Shapiro SD, Kobayashi DK, Pentland AP, Welgus HG. Induction of macrophage metalloproteinases by extracellular matrix. Evidence for enzyme- and substrate-specific responses involving prostaglandin-dependent mechanisms. J Biol Chem 1993; 268: 8170-8175
54. Lacraz S, Isler P, Vey E, Welgus HG, Dayer JM. Direct contact between T lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J Biol Chem 1994; 269: 22027-22033.
55. Malik N, Greenfield BW, Wahl AF, Kiener PA. Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996; 156: 3952-3960.
56. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998; 394: 200-203.
57. Hansson GK, Holm J, Jonasson L. Detection of activated T lymphocytes in the human atherosclerotic plaque. Am J Path 1989; 135: 169-175.
58. van der Wal AC, Das PK, Tigges AJ, Becker AE. Macrophage differentiation in atherosclerosis. An in situ immunohistochemical analysis in humans. Am J Pathol 1992; 141: 161-168.
59. Warner SJC, Auger KR, Libby P. Human interleukin 1 induces interleukin 1 gene expression in human vascular smooth muscle cells. J Exp Med 1987; 165: 1316-1331.
60. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990; 65: 297-302.
61. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
62. Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZG. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 1996; 98: 2572-2579.
63. Frears ER, Zhang Z, Blake DR, O'Connell JP, Winyard PC. Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett 1996; 381: 21-4.
64. Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993; 23: 118-126.
65. Lendon CL, Davies MJ, Born GV, Richardson PD. Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 1991; 87: 87-90.
66. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracelular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377-381.
67. Gibbons GH, Dzau VJ. The emerging concept of vascular remodeling. New Eng J Med 1994; 330: 1431-1438.
68. Langille BL. Remodeling of developing and mature arteries: endothelium, smooth muscle, and matrix. J Cardiovasc Pharmacol 1993; 21: S11-S17.
69. Nerem RM. Vascular fluid mechanics, the arterial wall, and atherosclerosis. J Biomech Eng 1992; 114: 274-282.
70. Wissler RW. New insights into the pathogenesis of atherosclerosis as revealed by PDAY Pathobiological Determinants of Atherosclerosis in Youth. Atherosclerosis 1994; 108: S3-S20.
71. Berliner JA, Navab M, Fogelman AM, et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation 1995; 91: 2488-2496.
72. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Atherosclerosis. American Heart Association. Circulation 1994; 89: 2462-2478.
73. Mignantti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195.
74. Stary HC, Chandler AB, Dinsmore RE et al. A definition of advanced types of atherosclerotic lesions and a histological classification of atheroscelerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis. American Heart Association. Circulation 1995; 92: 1355-1374.
75. Gerrity RG, Goss JA, Soby L. Control of monocyte recruitment by chemotactic factor(s) in lesion-prone areas of swine aorta. Arteriosclerosis 1985; 5: 55-66.
76. Fowler S. Characterization of foam cells in experimental atherosclerosis. Acta Med Scand 1980; 642 (suppl): 151-158.
77. Gerrity RG, Naito HK, Richardson M, Schwartz CJ. Dietary induced atherogenesis in swine: morphology of the intima in prelesion stages. Am J Pathol 1979; 95: 775-786.
78. Gimbrone MAJ, Bevilacqua MP, Cybulsky MI. Endothelial-dependent mechanisms of leukocyte adhesion in inflammation and atherosclerosis. An N Y Acad Sci 1990; 598: 77-85.
79. Cybulsky MI, Gimbrone Jr MA. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-791.
80. Li H, Cybulsky MI, Gimbrone Jr MA, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecula, in rabbit endothelium. Arteriosclerosis & Thrombosis 1993; 13: 197-204.
81. Spagnoli LG, Orlandi A, Santeusanio G. Foam cells of the rabbit atherosclerotic plaque arrested in metaphase by colchicine show a macrophage phenotype. Atherosclerosis 1991; 88: 87-92.
82. Romanic AM, Madri JA. The induction of 72-kD gelatinase in T-cells upon adhesion to endothelial cells is VCAM-1 dependent. J Cell Biol 1994; 125: 1165-1178.
83. Partridge CA, Jeffrey JJ, Malik AB. A 96-kDa gelatinase induced by TNF-alpha contributes to increased microvascular endothelial permeability. Am J Physiol 1993; 265: L438-L447.
84. Jackson CL, Reidy MA. The role of plasmminogen activation in smooth muscle cell migration after arterial injury. Ann NY Acad Sci 1992; 667: 141-150.
85. Zempo N, Kenagy RD, Au YPT et al. Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg 1994; 20: 209-217
86. Bendeck MP, Zempo N, Clowes AW, Galardy RE, Reidy MA. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994; 75: 539-545.
87. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996; 78: 38-43.
88. Forough R, Koyama N, Hasenstab D et al. Overexpression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circulation Research 1996; 79: 812-820.
89. Baker AH, Zaltsman AB, George SJ, Newby AC. Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest 1998; 101: 1478-1487
90. Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18: 1035-1045.
91. Jenkins GM, Crow MT, Bilato C et al. Increased expression of membrane-type matrix metalloproteinase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation 1998; 97: 82-90.
92. Bassiouny HS, Song RH, Hong XF, Singh A, Kocharyan H, Glasgov S. Flow regulation of 72-kD collagenase IV (MMP-2) after experimental arterial injury. Circulation 1998; 98: 157-163.
93. Glasgov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-1375.
94. Coats WD, Jr., Whittaker P, Cheung DT, Currier JW, Han B, Faxon DP. Collagen content is significantly lower in restenotic versus nonrestenotic vessels after balloon angioplasty in the atherosclerotic rabbit model. Circulation 1997; 95: 1293-1300.
95. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997; 15: 180-189.
96. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Research 1998; 58: 1048-1051
97. Vu TH, Shipley JM, Bergers G et al. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998; 93: 411-422.
98. Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992; 153: 557-562.
99. Murphy AN, Unsworth EJ, Stetler-Stevenson WG. Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993; 157: 351-358.
100. Werb Z, Tremble PM, Behrendtsen O, Crowley E, Damsky CH. Signal transduction through the fibronectin receptor induces collagenase and stromelysin gene expression. J Cell Biol 1989; 109: 877-889.
101. Huttenlocher A, Werb Z, Tremble P, Huhtala P, Rosenberg L, Damsky CH. Decorin regulates collagenase gene expression in fibroblasts adhering to vitronection. Matrix Biology 1996; 15: 239-250.
102. Brogi E, Winkles JA, Underwood R, Clinton SK, Alberts GF, Libby P. Distinct patterns of expression of fibroblast growth factors and their receptors in human atheroma and nonatherosclerotic arteries. Association of acidic FGF with plaque microvessels and macrophages. J Clin Invest 1993; 92: 2408-2418.
103. Wahl SM. Lymphocyte- and Macrophage-derived growth factors. Meth Enzymol 1988; 163: 715-731.
104. Nikkari ST, O'Brien KD, Ferguson M et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92: 1393-1398.
105. Fuster V, Stein B, Ambrose JA, Badimon L, Badimon JJ, Chesebro JH. Atherosclerotic plaque rupture and thrombosis. Circulation 1990; 82(suppl II): II-47 - II-59.
106. Falk E. Dynamics in thrombus formation. Ann NY Acad Sci 1992; 667: 204-223.
107. Lendon CL, Born GV, Davies MJ, Richardson PD. Plaque fissure: the link between atherosclerosis and thrombosis. Nouv Rev Fr Hematol 1992; 34: 27-29.
108. Constantinides P. Plaque hemorrhages, their genesis and their role in supra-plaque thrombosis and atherogenesis. In: Glasgov S, Newman WPI, Schaffer SA, (eds.) Pathobiology of the human atherosclerotic plaque. New York: Springer-Verlag, 1989; 393-412.
109. Farb A, Burke AP, Tang AL et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden and coronary death. Circulation 1996; 93: 1354-1363.
110. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT. Distribution of circumferential stress in ruptured and stable atherosclerotic lesions: a structural analysis with histopathologic correlation. Circulation. 1993; 87: 1179-1187.
111. Hansson GK, Jonasson L, Holm J, Clowes MK, Clowes A. Gamma Interferon regulates vascular smooth muscle proliferation and la expression in vivo and in vitro. Circ Research 1988; 63: 712-719.
112. Warner SJC, Friedman GB, Libby P. Immune interferon inhibits proliferation and induces 2′-5′-oligoadenylate synthetase gene expression in human vascular smooth muscle cells. J Clin Invest 1989; 83: 1174-1182.
113. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines positively and negatively regulate intersitial collagen gene expression in human vascular smooth muscle cells. Arteriosclerosis 1991; 11: 1223-1230.
114. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 1995; 91: 2125-2131.
115. Shah PK, Falk E, Badimon JJ et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995; 92: 1565-1569.
116. Galis ZS, Kranzhöfer R, Libby P. Thrombin promotes activation of matrix metalloproteinase-2 (MMP-2) produced by cultured smooth muscle cells. FASEBJ 1995; 9: A413.
117. Tryggvason K, Huhtala P, Hoyhtya M, Hujanen E, Hurskainen T. 70 K type IV collagenase (gelatinase). Matrix 1992; 1(suppl): 45-50.
118. Galis ZS, Kranzhöfer R, Fenton II J, Libby P. Thrombin promotes activation of matrix metalloproteinase-2 (MMP-2) produced by cultured smooth muscle cells. Arterioscl Thromb. Vasc Biol 1997; 17: 483-489.
119. Ward RV, Atkinson SJ, Slocombe PM, Docherty AJ, Reynolds JJ, Murphy G. Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta 1991; 1079: 242-246.
120. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW. Release of gelatinase A during platelet activation mediates aggregation. Nature 1997; 386: 616-619.
121. Herron GS, Unemori E, Wong M, Rapp JH, Hibbs MH, Stoney RJ. Connective tissue proteinases and inhibitors in abdominal aortic aneurysms. Involvement of the vasa vasorum in the pathogenesis of aortic aneurysms. Arterioscler Thromb Vasc Biol 1991; 11: 1667-1677.
122. Vine N, Powell JT. Metalloproteinases in degenerative aortic disease. Clin Sci (Colch) 1991; 81: 233-239.
123. Kim SC, Singh M, Huang J, et al. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 1997; 41: 642-666.
124. Newman KM, Jean-Claude J, Li H et al. Cellular localization of matrix metalloproteinases in the abdominal aortic aneurysm wall. J Vasc Surg 1994; 20: 814-820.
125. Freestone T, Turner RJ, Coady A, Higman DJ, Greenhalgh RM, Powell JT. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995; 15: 1145-1151.
126. McMillan WD, Tamarina NA, Cipollone M, Johnson DA, Parker MA, Pearce WH. Size matters: the relationship between MMP-9 expression and aortic diameter [see comments]. Circulation 1997; 96: 2228-2232
127. Schneiderman J, Bordin GM, Adar R et al. Patterns of expression of fibrinolytic genes and matrix metalloproteinase-9 in dissecting aortic aneurysms. Am J Pathol 1998; 152: 703-710.
128. Jean-Claude J, Newman KM, Li H, Gregory AK, Tilson MD. Possible key role for plasmin in the pathogenesis of abdominal aortic aneurysms. Surgery 1994; 116: 472-478.
129. Carmeliet P, Moons L, Lijnen R et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nature Genetics 1997; 17: 439-444.
130. Gordon JL, Drummond AH, Galloway WA. Metalloproteinase inhibitors as therapeutics. Clin Exp Rheumatol 1993; 11: S91-S94.
131. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995; 6: 967-974.
132. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Investigational New Drugs 1997; 15: 61-75.
133. Denis LJ, Verweij J. Matrix metalloproteinase inhibitors: present achievements and future prospects. Investigational New Drugs 1997; 15: 175-185.
134. Galis Z, Asanuma K, Godin D, Meng X. N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells: new target for antioxidant therapy? Circulation 1998; 97: 2445-2454.
135. Davies M. Reactive oxygen species, metalloproteinases, and plaque stability. Circulation 1998; 97: 2382-2384.